Article

CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease

2020-10-29

Abstract excerpt

<h4>Background</h4> Huntington’s Disease (HD) is a neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene for which no therapies are available. This mutation causes HTT protein misfolding and aggregation, preferentially affecting medium spiny neurons (MSNs) of the basal ganglia. Transcriptional perturbations in synaptic genes and neuroinflammation are key processes that precede...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b6cdf395-89c0-561b-a3f9-9ee20e7cfb06
DOI: 10.1101/2020.10.29.359380

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s diseaseDOI 10.1101/2020.10.29.359380Read

Silmitasertib, an FDA-designated orphan CK2 Inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington’s disease mouse modelSemantic proximity Read

Protein kinase CK2α’ as a dual modulator of immune signaling and synaptic dysfunction in TauopathySemantic proximity Read

Protein kinase CK2α’ as a dual modulator of neuroimmune signaling and synaptic dysfunction in TauopathySemantic proximity Read

Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2.Semantic proximity Read

Human Wild-Type α-Synuclein Drives Progressive Tau Pathology in a Disease-Relevant Mouse Model of SynucleinopathySemantic proximity Read

Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms.Semantic proximity Read

Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington’s DiseaseSemantic proximity Read

Kinases and Their Potential as Therapeutic Targets in Huntington’s DiseaseSemantic proximity Read

CK2 inhibition suppresses glial inflammation in the brainSemantic proximity Read

Deletion of the microglial transmembrane immune signaling adaptor TYROBP ameliorates Huntington’s disease mouse phenotypeSemantic proximity Read

<i>In vivo</i> MR spectroscopy reflects synapse density in a Huntington’s disease mouse modelSemantic proximity Read

Genetic and pharmacological reduction of CDK14 mitigates α-synuclein pathology in human neurons and in rodent models of Parkinson’s diseaseSemantic proximity Read